Oncology

Latest News

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com

Novel Biomarkers May Inform Prognosis in SCLC

By AJMC Contributor

June 6th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

By Rose McNulty

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

By Mary Caffrey

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com

5 Key FDA Approval Dates Mark a Milestone-Filled May

By Brooke McCormick

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

January 11th 2022

Diagnosis and Management of TRK Fusion Cancer

Shivaani Kummar, MD, FACP Antoine Italiano, MD, PhD Marcia S. Brose, MD, PhD Josh J. Carlson, PhD, MPH Sean D. Sullivan, PhD, MSc, RPh Ulrik Lassen, MD, PhD Noah Federman, MD

January 11th 2022

Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer

Josh J. Carlson, PhD, MPH Antoine Italiano, MD, PhD Marcia S. Brose, MD, PhD Noah Federman, MD Ulrik Lassen, MD, PhD Shivaani Kummar, MD, FACP Sean D. Sullivan, PhD, MSc, RPh

January 3rd 2022

Tennessee Oncology Names Dr Stephen Schleicher CMO, Dr Natalie Dickson CSO

Hayden E. Klein

Tennessee Oncology appointed Stephen Schleicher, MD, MBA, as Chief Medical Officer (CMO), with president Natalie Dickson, MD, being promoted from CMO to Chief Strategy Officer (CSO).

Burt Zweigenhaft, PhD, DLitt, Upstream Partners

December 20th 2021

CONFERENCE COVERAGE: Asembia 2021

Matthew Gavidia

Coverage from the Asembia 2021 Specialty Pharmacy Summit in Las Vegas.

December 20th 2021

PCOC Spotlight: There’s Been a Lot of Good for Patients With the OCM, Says US Oncology’s Neubauer

Laura Joszt, MA

Marcus Neubauer, MD, chief medical officer, The US Oncology Network. He is an expert in precision medicine, value-based care, and clinical pathways.

December 20th 2021

PCOC Spotlight: How Community Oncology Is a Low-Cost, High-Quality Provider

Laura Joszt, MA

Jeffrey Patton, MD, is the CEO of OneOncology, a national partnership of independent community oncologists based in Nashville, Tennessee. He is also executive chairman of the board, Tennessee Oncology, and a member of the board, Community Oncology Alliance.

December 20th 2021

In Oncology, Navigating PBMs Starts With Knowing What’s in the Contract

Mary Caffrey

Vertical integration of payers and pharmacy benefit managers (PBMs) took flight with the mergers of Aetna and CVS Health and of Cigna and ExpressScripts. Panelists at Patient-Centered Oncology Care® said the shift has filtered down to affect access at the practice level.

December 19th 2021

Panel Discusses the Ongoing Evolution of Remote Patient Care

Maggie L. Shaw

The discussion, "Remote Patient Monitoring: Case Studies From the Front Lines,” explored real-world experiences with technology that has taken on greater heft as the COVID-19 pandemic continues to affect health care delivery.

December 19th 2021

PCOC SPOTLIGHT: In Taking on Disparities, What Is Actionable? What Can We Share With the Nation?

Laura Joszt, MA

Karen Winkfield, MD, PhD, is the executive director of the Meharry-Vanderbilt Alliance, a strategic partnership between Meharry Medical College and Vanderbilt College of Medicine, Nashville, Tennessee. She is also Ingram Professor of Cancer Research and professor of radiation oncology, Vanderbilt-Ingram Cancer Center.

December 19th 2021

PCOC SPOTLIGHT: Patel Says Let the OCM Continue for Now

Laura Joszt, MA

The Oncology Care Model (OCM) is scheduled to end in just a few months, but with no new model in place to succeed it and practices still struggling during the pandemic, CMS should allow OCM to continue, said Kashyap Patel, MD, a co-chair of Patient-Centered Oncology Care® and the current president of the Community Oncology Alliance. He is CEO of Carolina Blood and Cancer Care Associates.

December 19th 2021

PCOC SPOTLIGHT: Empowering Stakeholders Across the Breadth of Oncology

Allison Inserro

Joseph Alvarnas, MD, a co-chair of Patient-Centered Oncology Care® (PCOC), discussed the unique nature of PCOC and what it offers for providers, payers, policy leaders, and technology experts who take part. Alvarnas is vice president, Government Affairs; senior medical director, employer strategy, and clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope.

December 13th 2021

Surveys Probe Biosimilars in Oncology

Tony Hagen

Recent surveys shed light on oncologist and patient perceptions of the switch to biosimilars and patient mental health.

December 9th 2021

Mental Health Distress Impacting Cancer Patients, Says New Cardinal Health Survey of Oncologists

More than 80% of oncologists frequently see mental health distress in their patients with cancer, and more than 90% say it has a significant impact on their health outcomes.

December 8th 2021

Flatiron Health Leverages Expertise With Real-World Data to Examine Cancer Care Disparities

Mary Caffrey

November 23rd 2021

Achieving Equitable Breast Cancer Care: Clinical Trials, Mental Health, and Digital Therapeutics

Matthew Gavidia

Discussions regarding health equity and access to care have long been implicated in breast cancer. Here, key opinion leaders discuss the latest progress in clinical trial access, digital therapeutics, and other efforts that aim to ameliorate these care gaps.

November 22nd 2021

Dr Karen van Caulil: End of Oncology Care Model Could Leave Gap in Comprehensive Care

Hayden E. Klein

Karen L. van Caulil, PhD, president and CEO of Florida Alliance for Healthcare Value, discusses the potential gap in care that may occur with the end of the Oncology Care Model.

November 22nd 2021

With No Replacement for OCM on Horizon, Oncology Practices Ask: What Now?

Gianna Melillo

The announcement of a "strategic refresh" for payment models under the Center for Medicare and Medicaid Innovation offered no details on what practices should expect when the Oncology Care Model (OCM) expires in 2022.

clipart images of an apple, pill bottle, healthcare forms, doctors, hand holding a heart, piggy bank with a calculator, and a stack of money

November 20th 2021

US Oncology Network, Tennessee Oncology Tout Medicare OCM Savings

Skylar Jeremias

A report from the Centers for Medicare and Medicaid Innovation confirmed that practices within the US Oncology Network and Tennessee Oncology participating in the Oncology Care Model (OCM) program have contributed significant savings to the agency.

November 20th 2021

Dr Funmi Olopade: Breast Cancer Screening Is Not One Size Fits All

Hayden E. Klein

Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains how different populations are at different risk for breast cancer and the importance of informed screening.

November 7th 2021

Contributor: Don’t Delay—Why Now Is the Time to Reengage Patients in Routine Cancer Screenings

Matt Dickson

Ignoring life-threatening, non–COVID-19 conditions for too long can turn one health crisis into another. Now is the time to resume cancer screenings, like mammograms and colonoscopies, because early detection can be lifesaving.

October 3rd 2021

Consolidative Radiation Therapy Improves Progression-Free Survival in DLBCL

Deanna Ferreri, PhD

This new study shows that consolidative radiation therapy may be of benefit to persons with diffuse large B-cell lymphoma, both bulky and nonbulky disease.

October 1st 2021

Dr Marcus Neubauer Outlines the Benefits of the OCM and the Potential Successor Model

The Oncology Care Model (OCM) was a great program that led to practice transformation and improved patient care, but there needs to be a way to address the high cost of cancer therapies, said Marcus Neubauer, MD, chief medical officer of the US Oncology Network.

Elizabeth Kwo, MD, MBA, MPH, deputy chief clinical officer at Anthem BCBS, a

September 29th 2021

Dr Elizabeth Kwo on Using Predictive Analytics to Curb Avoidable Hospitalizations During Cancer Therapy

Anemia, fevers, dehydration, and other side effects from cancer treatment are all candidates for targeting with predictive analytics in an effort to care for patients are home instead of the hospital, said Elizabeth Kwo, MD, MBA, MPH, the deputy chief clinical officer at Anthem BCBS, and a speaker at the 10th anniversary of Patient-Centered Oncology Care® conference.

Advances in Understanding of DLBCL Offer Prognostic and Theraptic Value

September 26th 2021

Surface Proteins in DLBCL Offer Therapeutic Targets

Deana Ferreri, PhD

Increasing knowledge of mutations and signaling proteins in diffuse large B-cell lymphoma (DLBCL) offer prognostic and therapeutic advantages, according to a review of recent findings.

September 19th 2021

Frontline Cemiplimab With Chemo Offers Benefits in Advanced NSCLC Regardless of PD-L1 Status

Mary Caffrey

Sanofi and Regeneron had previously announced an overall survival advantage of 29% over chemotherapy alone; the combination also had a progression-free survival benefit of 46%.

September 19th 2021

In HER2+ MBC, Trastuzumab Deruxtecan Slashes Risk of Disease Progression, Death by 72% vs T-DM1

Mary Caffrey

The prespecified analysis of DESTINY-Breast03 opened a Presidential Symposium September 18, during the European Society of Medical Oncology (ESMO) 2021 Virtual Congress, with the study’s lead author predicting a new standard of care and a commentator calling the results “startling.”

Young woman undergoing chemotherapy with physician.

September 14th 2021

Spotlighting Social, Emotional Needs in Underserved Populations With Cancer

Matthew Gavidia

Psychological and emotional needs specific to populations with cancer are often overlooked in clinical research, including those of adolescents, young adults, immigrants, and people of lower socioeconomic status.

September 8th 2021

Dr Gary Lyman: Pandemic Barriers Led to More Late-Stage Cancer Presentations

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how doctors are managing patients who present with later-stage cancers as a result of barriers to screening measures imposed by the pandemic.

September 5th 2021

Study: PET/CT Scans Predict for Response in Salvage-Stage DLBCL

Tony Hagen

For patients with diffuse large B-cell lymphoma (DLBCL), PET/CT scans conducted in the first cycle of salvage therapy can predict for response, according to a study.

August 29th 2021

A Review of Standard of Care in DLBCL

Tony Hagen

A review of treatment options in diffuse large B-cell lymphoma (DLBCL) addresses common subtypes and patient response to standard of care.

...

13 14 15 16 17 18 19 20 21

...

185 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions